We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microfiber Pad Helps Collect Uncontaminated Urine Samples

By LabMedica International staff writers
Posted on 27 Jan 2016
A new noninvasive microfiber pad draws urine samples in seconds, preventing cross-contamination during collection.

Developed by researchers of the BioDesign team at the Hebrew University (HUJI; Jerusalem, Israel) and Hadassah Medical Center (Jerusalem, Israel), the UCap microfiber urine collection pad contains bundles of hollow glass microfibers that quickly draw urine via capillary action from absorptive pads in just seconds. More...
The remainder of the urine is absorbed by a polymer matrix, thus preventing cross-contamination of the urine sample by contact with the patient’s skin or fecal matter.

The low-cost but highly effective solution can save time and money in the collection of sterile samples from patients especially prone to contract a urinary tract infection (UTI), including infants and bed-ridden hospitalized patients. While sterile urine samples can be readily collected in adults using simple plastic cups, urine collections in infants and hospitalized populations relies on adhesive plastic bags or on invasive catheters.

“Contamination of urine samples from infants and the elderly is so common that physicians often needlessly prescribe broad-spectrum antibiotics prophylactically, increasing the risk of developing antibiotic resistant bacteria,” said Amir Orlev, MD, who was part of the multidisciplinary BioDesign team set out to solve the problem under a medical innovation program.

“More than 11 million urine tests are carried out each year in infants and elderly patients. This presents a market of USD 100 million annually in the United States alone,” said BioDesign team member MBA student Itai Monnickendam. “Our low-cost urine collection pad has the potential to reduce pain and complications for millions of people and save time and expenditure for the healthcare system.”

Related Links:

Hebrew University of Jerusalem
Hadassah Medical Center



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
HPV Test
Allplex HPV28 Detection
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.